Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...

About an hour after the closing bell, shares of Emergent were trading 6.4% higher, at $7.31. The company's shares ended the day's regular session at $6.87, a gain of 3.7%.

Emergent BioSolutions (EBS) has secured a $51.9M contract modification award to deliver CNJ-016 to the Administration for Strategic Preparedness and Response (A ...

Investing.com -- Emergent BioSolutions Inc (NYSE: EBS) stock rose 6.3% after the company announced a contract modification to deliver additional doses of its smallpox vaccination complication ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for ...

South Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency ...

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...

The clinical trial support services market is experiencing significant growth, driven by the increasing incidence of chronic illnesses such as cancer ...

A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...

In this GEN panel discussion, three experts in cell and gene therapy development will share lessons and strategies learned ...

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000 ® Index, effective after the U.S.